Merck & Co. shareholders can go forward with a class-action suit alleging the company misrepresented the safety of its arthritis drug Vioxx and that share prices fell when the true risk was disclosed.
U.S. District Judge Stanley Chesler in Newark granted certification on Wednesday for a class of plaintiffs claiming the company’s statements violated the 1934 Securities Exchange Act.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
